- Open
- 118.00
- High
- 121.13
- Low
- 114.20
- Close
- 116.00
- Change
- -3.00 (-2.52%)
- Volume
- 991,051
| 3 Aug 2026 | 07:00:04 | Total Voting Rights |
| 31 Jul 2026 | 17:00:01 | PDMR Notification RSU Vesting |
| 17 Jul 2026 | 17:00:00 | PDMR Notification RSU Vesting |
| 13 Jul 2026 | 07:00:10 | PRTC: Celea Doses 1st Patient in Phase 3 IPF Trial |
| 9 Jul 2026 | 07:00:04 | Director/PDMR Shareholding |
| 29 Apr 2026 | Annual Report and Accounts 2025 | |
| 30 Apr 2025 | Annual Report and Accounts 2024 | |
| 25 Apr 2024 | Annual Report and Accounts 2023 |
PureTech Health PLC is a biotherapeutics company that focuses on the clinical development of therapies for severe diseases, including immunological, fibrotic, and inflammatory conditions. The company operates a hub-and-spoke model, advancing programs through Founded Entities, which are companies it has established to develop specific therapeutic candidates. PureTech generates revenue through equity interests and potential milestone payments from these entities, while also attracting external capital to support its initiatives. It operates primarily in the biotechnology sector, with a presence in Boston and the UK.
| 3 Aug 2026 | 07:00:04 | Total Voting Rights |
| 31 Jul 2026 | 17:00:01 | PDMR Notification RSU Vesting |
| 17 Jul 2026 | 17:00:00 | PDMR Notification RSU Vesting |
| 13 Jul 2026 | 07:00:10 | PRTC: Celea Doses 1st Patient in Phase 3 IPF Trial |
| 9 Jul 2026 | 07:00:04 | Director/PDMR Shareholding |
| 29 Apr 2026 | Annual Report and Accounts 2025 | |
| 30 Apr 2025 | Annual Report and Accounts 2024 | |
| 25 Apr 2024 | Annual Report and Accounts 2023 |
PureTech Health PLC is a biotherapeutics company that focuses on the clinical development of therapies for severe diseases, including immunological, fibrotic, and inflammatory conditions. The company operates a hub-and-spoke model, advancing programs through Founded Entities, which are companies it has established to develop specific therapeutic candidates. PureTech generates revenue through equity interests and potential milestone payments from these entities, while also attracting external capital to support its initiatives. It operates primarily in the biotechnology sector, with a presence in Boston and the UK.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £413m | -0.5% | |
PRTCPuretech Health PLC | £299m | -0.2% |
| £12m | +1.4% | |
| £12m | +0.5% | |
| £11m | -0.1% | |
| £1m | -0.8% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £413m | -0.5% | |
PRTCPuretech Health PLC | £299m | -0.2% |
| £12m | +1.4% | |
| £12m | +0.5% | |
| £11m | -0.1% | |
| £1m | -0.8% |